BackCannara Biotech Overview

Cannara Biotech Accounts Payable

Track Cannara Biotech's accounts payable ($11M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$10.63M
↓ 13.44% YoYΔ $-1.65M vs prior year quarter

Peer trimmed avg / median

Loading

Cannara Biotech Accounts Payable History

Loading

Cannara Biotech vs. peers: Accounts Payable Comparison

Loading

Cannara Biotech Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Cannara Biotech (LOVFF) FAQ

As of the most recent data (May 2026), LOVFF shows a accounts payable of $11M. That compares with $12M in the prior-year period — down 13.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LOVFF's accounts payable is now $11M (was $12M) — a 13.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Cannara Biotech is outperforming or lagging.

Tracking LOVFF's accounts payable over time shows whether Cannara Biotech is scaling, shrinking, or reshaping that part of the business. The current reading is $11M That compares with $12M in the prior-year period — down 13.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Cannara Biotech's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $11M) with ownership activity and broader fundamentals.

Questions & Answers